

CIRM Funded Clinical Trials

Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)

Disease Area:	COVID-19
Investigator:	Michael Matthay
Institution:	University of California, San Francisco
CIRM Grant:	CLIN2COVID19-11823
Award Value:	\$701,049
Trial Sponsor:	University of California, San Francisco
Trial Stage:	Phase 2
Trial Status:	Recruiting
Targeted Enrollment:	120
ClinicalTrials.gov ID:	NCT03818854



Michael Matthay

Details:

Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that occurs when fluid leaks into the lungs. As a result, breathing becomes difficult and oxygen cannot get into the body. ARDS is one of the most serious and lethal consequence of COVID-19.

This clinical trial will use Mesenchymal Stromal Cells (MSCs) for the treatment of ARDS, including both COVID-19 positive and COVID-19 negative patients, with the hopes of improving oxygenation.

Design:

Phase 2B trial

Goal:

Test safety and efficacy.

Source URL: <https://www.cirm.ca.gov/clinical-trial/mesenchymal-stromal-cells-ards-covid-positive-and-covid-negative>